Aptar Q3 2025 results show solid growth across its packaging and drug delivery divisions for the period ended September 30, 2025.
Reported sales rose 6% year on year to $961 million.
Core sales increased 1%. Reported net income was $128 million, up 28%. Diluted EPS came in at $1.92, up 30% versus last year. Adjusted EPS was $1.62. Adjusted EBITDA reached $223 million, with a 23.2% margin.
The company highlighted strong product volume in Pharma and Closures.
Injectables led the growth, with sales up 18% in the quarter. Management said the ramp in injectables supports a strong finish to the year for elastomeric components.
By segment, Aptar Pharma’s reported sales increased 6% and core sales rose 2% versus last year, helped by higher volumes in prescription drug dispensing systems, injectables, and active material science solutions. The Closures segment also delivered steady volume trends alongside the Pharma performance.
Year-to-date (nine months), reported sales increased 3% and core sales rose 1%.
Reported net income reached $318 million, and reported EPS was $4.75. Adjusted EPS was $4.48. Adjusted EBITDA totaled $624 million, with a 22.2% margin. The company returned $279 million to shareholders through buybacks and dividends over the nine-month period; $70 million was returned in Q3 alone.
The balance sheet and cash flow details support continued investment and shareholder returns. The company said it remains focused on innovation, operational excellence, and disciplined capital deployment to drive long-term growth.
Why It Matters
Aptar is a key packaging and drug-delivery supplier to FMCG and pharma.
When injectables grow fast, it signals strong demand for components used in biologics and GLP-1 therapies — areas with growing relevance to consumer health and wellness. Strong margins and cash returns also indicate stable pricing and capacity planning across closures, dispensing, and protective packaging systems. For supermarket suppliers and private-label manufacturers, steady packaging supply and innovation in dosing/dispensing reduce risk in product launches and new formulations.
Source note:
All information in this article is from Aptar’s official website and press release dated October 30, 2025. We carefully checked the release and official materials before writing this news.
